Objectives: Antibiotic therapy is of vital importance for the control of infectious exacerbations in cystic fibrosis (CF) patients. However, very little is known regarding the fraction of systemically administered antibiotics reaching the lower respiratory tract secretions. We developed and validated a method to measure the concentrations of piperacillin, ceftazidime, meropenem and aztreonam in CF sputum, and present the validation data.
Introduction
Intensive antibiotic therapy is a cornerstone of respiratory infection management in cystic fibrosis (CF) patients and has resulted in improved quality of life and increased survival. 1 With only a few new antimicrobials in the pipeline, judicious use of existing antibiotics is essential to limit the development of resistance while providing effective therapy.
2 Subtherapeutic doses at the infection site can induce bacterial resistance, with possible negative effects on the clinical outcome. [3] [4] [5] The effectiveness of an antibiotic treatment in CF patients is usually expressed in terms of improved forced expiratory volume in 1 s or eradication of the pathogen from sputum. 6, 7 For b-lactams, the time above the MIC in blood can also be considered. 7 Measuring antibiotic concentrations in the airway secretions would allow evaluation of whether sufficiently high concentrations of antibiotics are achieved for a sufficiently long time directly at the infection site.
A comprehensive review on existing methods of measuring pulmonary antibiotic concentrations revealed that only sputum easily allows pharmacokinetic studies or routine concentration measurements. 8 However, very few papers describing methods for determining antibiotic concentrations in sputum have been published. Older papers use bioassays or agar disc diffusion assays, which are time consuming and interpretation is often complicated by the growth of bacteria present in sputum. [9] [10] [11] [12] [13] V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Also, current treatment regimens usually combine several antibiotics, which does not allow straightforward concentration measurements of the individual compounds. For these reasons, HPLC with UV detection (HPLC-UV) was used as an alternative. However, except for Wilms et al., 18 the published HPLC-UV methods were based on existing methods optimized for plasma or urine and are thus not validated for use with CF sputum. [14] [15] [16] [17] [18] We developed and validated a protocol for sputum sample preparation and quantification of the b-lactam antibiotics ceftazidime, piperacillin, meropenem and aztreonam in expectorated sputum using LC coupled to tandem MS (LC-MS/MS). The validation was based on the EMA guideline on bioanalytical method validation. 19 Quantification of antibiotics in sputum may enable determination of the fraction of the antibiotic reaching the infection site, intra-and interpatient variation and the link between sputum concentrations and clinical outcome, to optimize treatment, to limit side effects and to minimize the risk of inducing resistance.
Materials and methods

Chemicals
Piperacillin, ceftazidime, bovine serum (BS), ammonium acetate and formic acid were purchased from Sigma-Aldrich (Bornem, Belgium) and meropenem and aztreonam from Molekula (München, Germany). Deuterated internal standards ceftazidime-D 5 , piperacillin-D 5 and meropenem-D 6 were purchased from Toronto Research Chemicals (Ontario, Canada) and aztreonam-D 6 was purchased from Alsachim (Illkirch, France). Acetonitrile and methanol were purchased from Merck (Darmstadt, Germany). For all experiments, reverse-osmosis-purified water was used (conductivity ,0.055 lS/cm, Elga DV 25 LabWater, Analis, Namur, Belgium).
Collection of sputum samples
Blank sputum was collected via expectoration from CF patients not recently treated with any of the target antibiotics. The collection was approved by the Ethics Committee of Ghent University Hospital (2014/1290) and the Belgian regulatory agency (B670201423054) and was conducted in accordance with the Declaration of Helsinki. All patients gave written informed consent.
Preparation of quality control (QC) samples
QC samples were prepared using pooled blank sputum from 18 different patients (final volume +15 mL). The pooled samples were liquefied by vigorous shaking for 1 min in a 50 mL plastic tube. An aqueous stock solution was prepared by a method similar to that described for the preparation of the calibration levels. QC samples were prepared by diluting the appropriate amount of this aqueous stock solution with the pooled sputum. Four different concentration levels were prepared (Table 1) . Special care was taken to ensure that the amount of aqueous antibiotic solution added to the four concentration levels was always 1:10 (v/v, water:sputum).
Calibration curve
Ceftazidime, piperacillin, meropenem and aztreonam were dissolved in water at final concentrations of 1000, 1600, 400 and 800 mg/L, respectively. The most concentrated calibration level, the upper limit of quantification (ULoQ), was prepared by 1:10 (v/v) dilution of this stock solution with pure BS. Aliquots of 100 lL were stored in microfuge tubes at #80 C until use. A total of seven calibration levels (Table 1) were used. The six lower calibration levels were freshly prepared by dilution of the most concentrated calibration level with BS.
To determine the best weighting and fitting scheme, five separate calibration curves were analysed in a single analytical run. The percentage relative error (% RE) was calculated for each calibration level using a linear or quadratic fitting combined with 1/x, 1/x 2 , 1/y or 1/y 2 weighting. The sum of the % RE values was calculated over the five repetitions and used to determine the most appropriate calibration model. 20 Sample preparation for LC-MS/MS analysis First, 0.1 mL of sputum, QC sample or calibrator was diluted with 0.1 mL of water. Depending on the validation experiment, antibiotics for spiking and/or internal standards were added to this water prior to sputum dilution. When analysing patient samples, only an internal standard was added at this step. After brief vortexing (3200 rpm), the mixture was boiled for 2 min in a closed container using a water bath and cooled rapidly using cold water, briefly vortexed again and centrifuged at 16000 g for 5 min (Microfuge 16, Beckman Coulter, Fullerton, CA, USA) to remove heavier, denatured sputum components. Twenty microlitres of the supernatant was added to 0.1 mL of acetonitrile and placed in an orbital shaker (5 min, 1400 rpm, 7 C, Thermomixer Comfort, Eppendorf). Precipitated proteins were removed by centrifugation (16000 g for 5 min) and 0.1 mL of the supernatant was added to 0.4 mL of water in a vial with preslit screw cap (La-Pha-Pack, Langerwehe, Germany) and briefly vortexed.
Sample preparation for the calibrators was similar to the procedure described for sputum. However, the boiling step was omitted, as this step is redundant in the case of serum.
Chromatographic and MS conditions
The samples were analysed using a Waters ACQUITY Ultra Performance LC (UPLC) system coupled to a triple-quadrupole mass spectrometer (TQD) (Waters, Milford, MA, USA) based on a method for plasma developed in our laboratory. 21 Sample separation was performed on an ACQUITY UPLC BEH C18 column (100%2.1 mm, 1.7 lm particle size) equipped with a 0.2 lm precolumn filter unit and a 2.1%5 mm BEH C18 VanGuard TM guard column (Waters). Data were acquired and analysed using the MassLynx v.4.1 and QuanLynx v.4.1 software (Waters). Table 1 . Target concentrations (mg/L) for QC samples (in sputum) and calibration levels (Cal; in BS); the used concentrations of the internal standards (deuterated forms of the antibiotics) are also displayed . The starting conditions were 98% A and 2% B. After 0.5 min, the ratio was switched abruptly to 2% A and 98% B and this was maintained for 1 min, after which the gradient was abruptly switched back to starting conditions, which were maintained for 1 min. The flow rate was 0.4 mL/min.
The MS/MS detector capillary voltage was set to 3.00 kV and the RF lens and extractor were set to 0.5 and 3 V, respectively. The source temperature was maintained at 140 C and desolvation gas (nitrogen) temperature at 400 C with a flow of 800 L/h. Positive electrospray ionization was used. Multiple reaction monitoring (MRM) of selected precursor and product ions was used for analyte quantification. The optimal mass-to-charge ratios and voltages were obtained via post-column infusion using the AutoTune Wizard. Table 2 summarizes the optimized settings for the b-lactam antibiotics and their deuterated internal standards.
Selectivity and specificity
Sputum samples from eight different CF patients were individually analysed to demonstrate the absence of interfering compounds. Blank samples were prepared by processing the sputum without the addition of antibiotic or internal standard.
To evaluate interference caused by the internal standard, zero samples were prepared using pooled CF sputum spiked with only internal standard (n " 3). Similarly, pooled sputum spiked with only the native antibiotic at the ULoQ was used to evaluate interference caused by the antibiotic (n " 3).
QC at the lower limit of quantification (QC-LLoQ) and QC at low concentration (QCL) samples, to all of which internal standard was added, were also prepared to compare the peak areas with those obtained for the blank, zero and ULoQ samples. The concentrations used can be found in Table 1 .
Accuracy, precision and LLoQ
Both within-and between-run accuracy and precision were measured using the four QC levels. Within-run accuracy and precision were measured in a single analytical run of five replicates per QC level, together with seven calibrators. The between-run accuracy and precision were evaluated by comparing the results from runs measuring the four QC levels and seven calibration levels on seven different days.
The mean concentration of QCL, QC at medium concentration (QCM) and QC at high concentration (QCH) samples should be within +15% of the nominal concentration and the coefficient of variation (CV) within 15%.
For the QC-LLoQ, deviations no larger than 20% were tolerated with respect to the nominal concentration and CV. 19 The signal of the QC with lowest concentration that could be measured with acceptable accuracy and precision (LLoQ) was compared with the signal of blank sputum samples (n " 3). The analyte signal of the LLoQ should be at least 5 times the signal of a blank sample to comply with the EMA guideline. 19 
Carry-over
Carry-over was assessed by injecting blank BS samples directly after injection of calibrator 7 (ULoQ). Internal standards were added to all but the blank samples at the concentrations listed in Table 1 . The peak areas of the different antibiotics and internal standards in the blank samples were compared with LLoQ sample areas (n " 6). No significant carry-over was present if the peak areas of the analyte and internal standard in the blank sample were ,20% of the area of the LLoQ or ,5% of the area of the internal standard, respectively. 19 
Matrix effect and recovery
The matrix effect and recovery were evaluated using the method of Matuszewski et al. 22 Sputum samples from eight individual CF patients were used. Three sets of samples were made: aliquots of the individual sputum samples spiked before extraction, after extraction and spiked neat mobile phase (mixture of 98% mobile phase A, 2% mobile phase B, n " 4). Low (maximum 3 % LLoQ) and high (90% of the ULoQ) concentrations of the antibiotics were spiked (Table 3) .
For the matrix effect, the CV of the internal standard normalized matrix factor (MF) for the eight samples should not exceed 15%. 19 The recovery was calculated by comparing responses of sputum samples spiked before and after extraction ( Table 3 ). The CV should not exceed 15% to be acceptable.
Short-term stability at room temperature
Three QCL and QCH samples were kept at room temperature for 1 h prior to sample preparation, while three other QCL and QCH samples were immediately processed. Concentration deviations of .15% between the two sets suggest instability at room temperature.
Autosampler stability QCL and QCH samples were prepared and analysed immediately (n " 3). After overnight incubation for 15 h in the autosampler (4 C), the QC samples were analysed again. The average concentration after incubation should not differ by .15% from the original concentrations. 
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Freeze-thaw stability
The freeze-thaw stability of the antibiotics while dissolved in CF sputum was assessed using QCL and QCH samples. The concentration of the QC samples was measured directly after spiking and again after one, two and three freeze-thaw cycles. The samples were frozen again for 24 h after reaching room temperature (n " 3). Deviations of .15% from the initial concentration indicated freeze-thaw instability.
Long-term stability
The long-term stability of the antibiotics while dissolved in CF sputum at #80 C was assessed over 6 weeks using QCL and QCH samples, which is more than reasonable to allow the analysis and, if necessary, reanalysis of stored patient samples. The QC concentrations after 2, 4 and 6 weeks at #80 C were compared with the concentrations directly after spiking (n " 3). Deviations of .15% indicated instability at #80 C or due to the thawing process.
Results
Calibration curve
For ceftazidime, piperacillin and meropenem, all weighting and fitting schemes resulted in minor differences in the sum of % RE values. For these compounds, linear regressions with weighting factors of 1/x, 1/x and 1/x 2 , respectively, were chosen because a linear curve requires fewer estimated factors compared with a quadratic curve. For aztreonam, quadratic curves resulted in the lowest sum % RE, with an optimal weighting of 1/x (Table S1, available as Supplementary data at JAC Online).
Selectivity and specificity
No interfering compounds were detected in the eight blank patient samples. When spiking sputum with the deuterated internal standards (zero samples), the absence of unlabelled isotopes was confirmed. Similarly, when spiking sputum with antibiotics at the highest concentration, no peaks were observed in the chromatograms of the internal standards.
Carry-over
For meropenem, ceftazidime and all internal standards, no carryover was observed in the blank samples. Peaks were observed in the chromatograms of the blank samples for piperacillin and aztreonam, but carry-over was within the specified limits (Table S2 ).
Accuracy and precision
The results are summarized in Table 4 . The accuracy was within the EMA limits for all compounds. Only the between-run precision for the meropenem LLoQ samples, with a CV of 23%, lay outside the 20% limit. The LLoQ for this compound was therefore set at 0.72 mg/L.
For ceftazidime, piperacillin, meropenem and aztreonam, the signal was 17, 160, 37 and 191 times higher than the blank, respectively (Table S3) .
Matrix effect and recovery
The average MF calculated over the eight sputum samples ranged between 72% and 153%. For low concentrations of ceftazidime and meropenem, ion enhancement was observed. In all other cases, ion suppression took place. The use of an internal standard offered a good compensation for this effect, as the internal standard normalized MF ranged between 88% and 111% Based on the internal standard normalized MF, the CV was calculated for all eight sputum samples. As the CV ranged from 2% to 10%, the EMA guideline requirements were met. The recovery ranged between 87% and 105%, with CVs below the 15% limit (Table 3) .
Short-term stability at room temperature
Ceftazidime, meropenem and aztreonam were stable for 1 h at room temperature. For piperacillin the concentration deviated .15% from the initial concentration, namely #75% and #49% for the QCL and QCH samples, respectively (n " 3) (Table S4 ). Ratio of peak area of the sputum samples to the peak area of the neat mobile phase samples.
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Autosampler stability
For ceftazidime, meropenem and piperacillin, the concentration deviations were ,7% after 15 h of incubation in the autosampler. For aztreonam, the concentrations of the QCL and QCH samples deviated by 21% and #11%, respectively (Table S5 ). The QCL was therefore outside the limits set by the EMA guideline.
Freeze-thaw stability
Ceftazidime, meropenem and aztreonam were freeze-thaw stable, with reductions in concentration ,15%. Freeze-thaw instability was observed for piperacillin. For the QCL samples, the concentrations were 44%, 73% and 83% lower than the initial concentration after one, two and three freeze-thaw cycles. For the QCH samples, this was #22%, #45% and #55% (Table S6) .
Long-term stability
Stability at #80 C was assessed over 6 weeks. The concentration changes are visualized in Figure 1 and an overview can be found in Table S7 . For meropenem, no instability was observed during this period. For piperacillin, deviations of .15% from the initial concentration, namely #40%, #36% and #38% for QCL samples at weeks 2, 4 and 6, were observed. For the QCH samples, the deviations were #16%, #11% and #12%. For ceftazidime, the QCL samples deviated by #1%, #18% and 0.49% and the QCH samples deviated by 7%, #1% and 15% from the initial concentration after 2, 4 and 6 weeks at #80 C. Only the second timepoint of QCL was therefore outside the limits. For aztreonam, the QCL samples deviated by 13%, #5% and 0.22% and the QCH samples deviated by 10%, 11% and 23% from the initial concentration after 2, 4 and 6 weeks at #80 C. The final timepoint of the QCH was outside the limits.
Discussion
UPLC-MS is increasingly used in the clinical laboratory, from diagnosing metabolic disorders to therapeutic drug monitoring. [23] [24] [25] This method is attractive for the quantification of individual antibiotics in sputum of CF patients due to its high specificity and the ability to measure multiple compounds within short periods of time. We have developed and validated a technique for CF sputum sample preparation and subsequent UPLC-MS/MS analysis for the quantification of ceftazidime, piperacillin, meropenem and aztreonam. Sample collection is non-invasive and only 0.1 mL of sputum is required. As mucus clearance is a daily routine in therapy, the burden on patients is limited.
BS was used to prepare the calibration levels, because blank CF sputum is difficult to obtain. BS can be purchased with a certificate of analysis and its composition will be more consistent compared with pooled sputum, leading to a more robust analysis. During validation, it was demonstrated that the concentrations of the QC samples could be accurately and precisely determined with a BSbased calibration curve.
Because CF sputum has a gel-like consistency and is mainly composed of mucins, filamentous DNA, actin and human and bacterial cell debris, purification of sputum samples is needed to avoid interference and instrument contamination. 26 We established that boiling the mucus for 2 min provided a fast method of sputum liquefaction, a necessary step to ensure an accurate concentration measurement. The presence of internal standards compensates for any temperature-induced degradation of the antibiotics and boiling did not result in sensitivity issues. Additionally, the complex Accuracy is expressed as the difference between the nominal and mean measured concentrations while precision is expressed as the CV of the measured concentration.
a Not compliant with the EMA guideline.
LC-MS/MS quantification of b-lactam antibiotics in sputum sputum composition could influence the recovery after sample preparation. Recovery tests are not included in the EMA guidelines, but by analogy of the matrix effect, the observed recovery showing CVs ,15% allowed reliable measurements. On top of the complex CF sputum composition, CF patients are heavily co-medicated. 27 Selectivity and specificity tests showed that the method is able to differentiate the analytes and internal standards from endo-and exogenous compounds in sputum. The absence of peaks in the chromatograms of injected blank sputum samples further confirms that these compounds do not bias the analysis.
As the analysis is based on MRM and is therefore selective for the target antibiotic, a full chromatographic separation of the antibiotics is not necessary. The fast gradient limits the analysis time to 2.5 min per sample, increasing the throughput of the method. However, co-elution of the analytes and other compounds could influence the analysis. Indeed, a matrix effect, mainly ion suppression, was seen, but this could be compensated for by using internal standards. The CV was well within the 15% limit, indicating a consistent matrix effect.
Accuracy and precision were found to be within limits for the evaluated calibration range, except for meropenem, where the LLoQ was adjusted from 0.36 to 0.72 mg/L. No carry-over was observed after injection of high antibiotic concentrations.
Stability of the stock and working solutions of the antibiotics and the working solutions of the internal standards was not evaluated, as these are to be freshly prepared. Strong degradation of piperacillin in sputum during a 1 h incubation at room temperature was observed. Therefore, it is recommended that the samples should be prepared and internal standards added immediately upon reception. If this is not possible, samples should be placed on ice. Piperacillin in sputum was stable for at least 5 h when placed on ice (data not shown). Moreover, piperacillin should be measured on the day of sample collection, as freeze-thaw cycles have a negative impact on the accuracy of the analysis of this compound. For the three other antibiotics, freezing the samples until analysis is an option. Meropenem and ceftazidime were stable for 6 weeks and aztreonam up to 4 weeks at #80 C. If prepared samples kept overnight in the cooled autosampler need to be reanalysed, possible effects on accuracy should be considered. No negative effect on accuracy was observed for ceftazidime, piperacillin and meropenem. For aztreonam, loss of accuracy was observed only at low concentrations. Therefore, it is recommended that analysis results for aztreonam should be evaluated as soon as possible, so that reanalysis can be initiated in ,15 h.
The proposed method is compliant with the EMA guideline on bioanalytical method validation and therefore allows a reliable measurement of the selected antibiotics. Sputum concentration measurements could provide insight into the antibiotic concentrations achieved in the lung secretions of CF patients, deepening our understanding of how individual patients respond to therapy. Forier et al.
Further research should focus on the distribution of the antibiotics in real patient samples. As sputum samples often have a heterogeneous consistency, this may lead to unequal distribution of the antibiotic in the collected sample. In addition, it will likely be necessary to standardize the way samples are collected in order to achieve a representative measurement.
